Arizona State University

Georgia Tech Research Corporation

University of Minnesota

Florida State University Research Foundation, Inc.

Arizona Board of Regents, a Body Corporate

Finch Therapeutics Holdings LLC

Pitt Hopkins Research Foundation

Rosa Krajmalnik-Brown

Bruce E Rittmann

Dae-Wook Kang

Joshua LaBaer

James Adams

Jin Park

Cesar Torres

Frank Loeffler

Sudeep Popat

Prathap Parameswaran

Kirsti M Ritalahti

Zehra Ilhan

Ivy Thomson

Thomas Julius Borody

Michael J Sadowsky

Alexander Khoruts

Youneng Tang

Zhaocheng Wang

Anca Delgado

Zehra IIhan

Yihao Luo

Srivatsan Mohana Rangan

Audrey Davidow

Chen Zhou

Aura Ontiveros-Valencia

Andrew Marcus

Michael Crowell

John Dibaise

Husen Zhang

Provided herein are compositions and methods for treating Pitt Hopkins Syndrome (PTHS) by restoring PTHS patient's gut microbiota. These methods can be used with PTHS patient with or without ongoing gastrointestinal symptoms. The methods comprise administering a therapeutic composition comprising a fecal microbe or a fecal microbe preparation to the subject.

Microbiota transfer therapy for Pitt Hopkins Syndrome

Disclosed herein are systems and methods for removing trichloroethane (TCA), trichloroethene (TCE), and 1,4-dioxane (1,4-D) from contaminated liquids. The system and methods rely on catalyst reduction of TCA and TCE, where the reduced products are then degraded by microorganisms The system comprises a first reactor comprising a catalyst film of precious metal nanoparticles deposited on a first nonporous membrane and a second reactor comprising a biofilm of microorganisms that are capable of degrading ethane and 1,4-D deposited on a second nonporous membrane. The first reactor further comprises a hydrogen gas source, wherein the hydrogen gas source delivers hydrogen to the gas-phase side of the first nonporous membrane, and the catalyst film is deposited on the liquid-phase side. The second reactor further comprises an oxygen gas source, wherein the oxygen gas source delivers oxygen to the gas-phase side of the second non-porous membrane, and the biofilm is deposited on the liquid-phase side.

Methods and systems for removing trichloroethane, trichloroethene, and 1,4-dioxane from contaminated water and wastewater

Methods and systems for the detection and quantification of multiplicity of ionic analytes comprising CrO, AsO, SeO, and ClO, and optionally F, Cl, NO, NO, SO, using ion chromatography and suppressed ion conductivity. The method comprises loading a sample loop with a sample; injecting the sample from the sample loop into a column with an eluent, wherein the column comprises a guard column and an analytical column; separating, with the column, the injected sample at an effective separation temperature the injected sample in the presence of an organic modifier into a multiplicity of detectable ionic analytes; suppressing, with a suppressor, background signal; and detecting, with a detector, the multiplicity of ionic analytes.

Methods for simultaneous quantification of anions using ion chromatography and suppressed ion conductivity

The present disclosure provides for characterization of normal flora and identifying biomarkers in the gut of healthy, neurotypical subjects. Aspect of the disclosure provide for the characterization of the gut microbiome in ADS subjects, characterized by reduced richness and significant loss of the '-like enterotype' compared to neurotypical subjects. The relative abundance of generaandare significantly lower in autistic children than in neurotypical children. Further,, is one of the three main classifiers for the human enterotypes, along with Bacteroides and. These three core genera are among main contributors in the principle component analysis. ‘-like enterotype’ was absent in the autistic group, while neurotypical samples showed an even distribution among the three enterotypes. The present disclosure provides for an understanding the association between gut microbiota, health, and disease states, and provides for potential diagnostic and therapeutic targets.

Microbiome markers and therapies for autism spectrum disorders

The present disclosure provides for characterization of normal flora and identifying biomarkers in the gut of healthy, neurotypical subjects. Aspect of the disclosure provide for the characterization of the gut microbiome in ADS subjects, characterized by reduced richness and significant loss of the '-like enterotype' compared to neurotypical subjects. The relative abundance of genera, Prevotellaceae and Veillonellaceae are significantly lower in autistic children than in neurotypical children. Further,is one of the three main classifiers for the human enterotypes, along withandThese three core genera are among main contributors in the principle component analysis. '-like enterotype' was absent in the autistic group, while neurotypical samples showed an even distribution among the three enterotypes. The present disclosure provides for an understanding the association between gut microbiota, health, and disease states, and provides for potential diagnostic and therapeutic targets.

The present invention relates to systems and methods for removing and recovering precious metals, such as platinum-group metals (PGMs), including palladium, from wastewater and waste streams. The invention also relates to systems and methods for recycling the recovered precious metals for catalytic applications.

Methods of recovering platinum group metals from waste streams

The present disclosure relates to compositions and methods for treating autism spectrum disorder (ASD) by restoring an ASD patient's gut microbiota. These methods can be used with ASD patient with or without ongoing gastrointestinal symptoms. Provided here is a method for modulating the abundance of one or more gut microorganisms in a subject in need thereof, said method comprising administering to said subject a therapeutically effective amount of a pharmaceutical composition comprising a fecal microbe preparation to achieve at least a 2-fold change of the abundance of said one or more fecal microorganisms, wherein said one or more gut microorganisms are selected from the group consisting of, and

Methods for treating autism spectrum disorder and associated symptoms

The present disclosure relates to compositions and methods for treating autism spectrum disorder (ASD) by restoring an ASD patient's gut microbiota. These methods can be used with ASD patient with or without ongoing gastrointestinal symptoms. Provided here is a method for ASD treatment in a subject in need thereof comprising or consisting essentially of administering a therapeutic composition comprising a fecal microbe or a fecal microbiota preparation to the subject. Also provided here is a method comprises administering an antibiotic to a human subject; subjecting the human subject to a bowel cleanse; and administering purified fecal microbiota to the human subject. Further provided are evaluation and quantitative characterization of patient symptom improvements upon treatment described here.

The present disclosure is directed toward membrane biofilm reactors primarily comprising microorganisms that produce chemical fuel products or precursors thereof. Reactors of the present disclosure can primarily comprise acetogens, a methanotrophs, and/or

Membrane biofilm reactors, systems, and methods for producing organic products

A membrane biofilm reactor including a vessel defining a volume is disclosed. The reactor also typically includes a first and second plurality of hollow fiber membranes. Each hollow fiber membrane generally has an outer surface and a lumen, and is located within the volume. The reactor further preferably includes a first and second gas feedstock. The first gas feedstock is provided through a first inlet in fluid communication with the lumens of the first plurality of hollow fiber membranes. The second gas feedstock is provided through a second inlet in fluid communication with the lumens of the second plurality hollow fiber membranes. Finally, the reactor also typically includes a biofilm formed on the outer surface of the hollow fiber membranes and made up of methanotrophs,, or both. The first gas feedstock is preferably different from the second gas feedstock.

The present disclosure provides for characterization of normal flora and identifying biomarkers in the gut of healthy, neruotypical subjects. Aspect of the disclosure provide for the characterization of the gut microbiome in ADS subjects, characterized by reduced richness and significant loss of the '-like enterotype' compared to neurotypical subjects. The relative abundance of genera, Prevotellaceae and Veillonellaceae are significantly lower in autistic children than in neurotypical children. Further,, is one of the three main classifiers for the human enterotypes, along withand. These three core genera are among main contributors in the principle component analysis. '-like enterotype' was absent in the autistic group, while neurotypical samples showed an even distribution among the three enterotypes. The present disclosure provides for an understanding the association between gut microbiota, health, and disease states, and provides for potential diagnostic and therapeutic targets.

The present invention provides for microbial compositions and methods for reducing the concentration of short-chain fatty acids in the gut as a way to reduce energy uptake and manage obesity. More specifically, the invention provides for decreasing short-chain fatty acids available for absorption in the human gut, such as acetate, using one or more of: a probiotic including a homo-acetogenic, acetate oxidizing bacterium that converts acetate to H; a probiotic including an acetoclastic methanogen; a microbial electrolysis cell comprising a homo-acetogenic bacterium and/or an acetoclastic methanogen; a prebiotic that enhances the growth or function of acetate-scavenging microbiota; or a highly selective antibiotic that targets H-oxidizing methanogens.

Reducing short-chain fatty acids and energy uptake in obese humans by managing their intestinal microbial communities

The invention is directed to novel reductive dehalogenase genes encoding for reductive dehalogenases which are capable of dehalogenating halogenated organic compounds and may be useful in the bioremediation of pollutants. In particular, the invention provides an isolated polynucleotide of a novel vinyl chloride dehalogenase gene (bvcA). The novel vinyl chloride dehalogenase gene encodes a reductive dehalogenase that is capable of the complete reduction of vinyl chloride to ethene.

Growing community of inventors

Chandler, AZ, United States of America

Rosa Krajmalnik-Brown